400 related articles for article (PubMed ID: 22907596)
1. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer.
Pienta KJ; Machiels JP; Schrijvers D; Alekseev B; Shkolnik M; Crabb SJ; Li S; Seetharam S; Puchalski TA; Takimoto C; Elsayed Y; Dawkins F; de Bono JS
Invest New Drugs; 2013 Jun; 31(3):760-8. PubMed ID: 22907596
[TBL] [Abstract][Full Text] [Related]
2. A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors.
Sandhu SK; Papadopoulos K; Fong PC; Patnaik A; Messiou C; Olmos D; Wang G; Tromp BJ; Puchalski TA; Balkwill F; Berns B; Seetharam S; de Bono JS; Tolcher AW
Cancer Chemother Pharmacol; 2013 Apr; 71(4):1041-50. PubMed ID: 23385782
[TBL] [Abstract][Full Text] [Related]
3. Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.
Brana I; Calles A; LoRusso PM; Yee LK; Puchalski TA; Seetharam S; Zhong B; de Boer CJ; Tabernero J; Calvo E
Target Oncol; 2015 Mar; 10(1):111-23. PubMed ID: 24928772
[TBL] [Abstract][Full Text] [Related]
4. Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data.
Fetterly GJ; Aras U; Meholick PD; Takimoto C; Seetharam S; McIntosh T; de Bono JS; Sandhu SK; Tolcher A; Davis HM; Zhou H; Puchalski TA
J Clin Pharmacol; 2013 Oct; 53(10):1020-7. PubMed ID: 23878055
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer.
Heidenreich A; Rawal SK; Szkarlat K; Bogdanova N; Dirix L; Stenzl A; Welslau M; Wang G; Dawkins F; de Boer CJ; Schrijvers D
Ann Oncol; 2013 Feb; 24(2):329-336. PubMed ID: 23104724
[TBL] [Abstract][Full Text] [Related]
6. A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer.
Hudes G; Tagawa ST; Whang YE; Qi M; Qin X; Puchalski TA; Reddy M; Cornfeld M; Eisenberger M
Invest New Drugs; 2013 Jun; 31(3):669-76. PubMed ID: 22828917
[TBL] [Abstract][Full Text] [Related]
7. A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer.
Chu FM; Picus J; Fracasso PM; Dreicer R; Lang Z; Foster B
Invest New Drugs; 2011 Aug; 29(4):674-9. PubMed ID: 20145975
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
Ning YM; Gulley JL; Arlen PM; Woo S; Steinberg SM; Wright JJ; Parnes HL; Trepel JB; Lee MJ; Kim YS; Sun H; Madan RA; Latham L; Jones E; Chen CC; Figg WD; Dahut WL
J Clin Oncol; 2010 Apr; 28(12):2070-6. PubMed ID: 20308663
[TBL] [Abstract][Full Text] [Related]
9. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.
Smith MR; Saad F; Coleman R; Shore N; Fizazi K; Tombal B; Miller K; Sieber P; Karsh L; Damião R; Tammela TL; Egerdie B; Van Poppel H; Chin J; Morote J; Gómez-Veiga F; Borkowski T; Ye Z; Kupic A; Dansey R; Goessl C
Lancet; 2012 Jan; 379(9810):39-46. PubMed ID: 22093187
[TBL] [Abstract][Full Text] [Related]
10. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
Fizazi K; De Bono JS; Flechon A; Heidenreich A; Voog E; Davis NB; Qi M; Bandekar R; Vermeulen JT; Cornfeld M; Hudes GR
Eur J Cancer; 2012 Jan; 48(1):85-93. PubMed ID: 22129890
[TBL] [Abstract][Full Text] [Related]
11. Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial.
Antonarakis ES; Carducci MA; Eisenberger MA; Denmeade SR; Slovin SF; Jelaca-Maxwell K; Vincent ME; Scher HI; Morris MJ
Cancer Chemother Pharmacol; 2012 Mar; 69(3):763-71. PubMed ID: 22020316
[TBL] [Abstract][Full Text] [Related]
12. CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab.
Raghu G; Martinez FJ; Brown KK; Costabel U; Cottin V; Wells AU; Lancaster L; Gibson KF; Haddad T; Agarwal P; Mack M; Dasgupta B; Nnane IP; Flavin SK; Barnathan ES
Eur Respir J; 2015 Dec; 46(6):1740-50. PubMed ID: 26493793
[TBL] [Abstract][Full Text] [Related]
13. Targeting the CCL2-CCR2 signaling axis in cancer metastasis.
Lim SY; Yuzhalin AE; Gordon-Weeks AN; Muschel RJ
Oncotarget; 2016 May; 7(19):28697-710. PubMed ID: 26885690
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07).
Cathomas R; Rothermundt C; Klingbiel D; Bubendorf L; Jaggi R; Betticher DC; Brauchli P; Cotting D; Droege C; Winterhalder R; Siciliano D; Berthold DR; Pless M; Schiess R; von Moos R; Gillessen S;
Clin Cancer Res; 2012 Nov; 18(21):6049-57. PubMed ID: 22977195
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium.
Alva A; Slovin S; Daignault S; Carducci M; Dipaola R; Pienta K; Agus D; Cooney K; Chen A; Smith DC; Hussain M
Invest New Drugs; 2012 Apr; 30(2):749-57. PubMed ID: 21049281
[TBL] [Abstract][Full Text] [Related]
16. Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus Doxorubicin in the treatment of metastatic castration-resistant prostate cancer.
Slovin SF; Kelly WK; Wilton A; Kattan M; Myskowski P; Mendelsohn J; Scher HI
Clin Genitourin Cancer; 2009 Oct; 7(3):E77-82. PubMed ID: 19815486
[TBL] [Abstract][Full Text] [Related]
17. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
Reid AH; Attard G; Danila DC; Oommen NB; Olmos D; Fong PC; Molife LR; Hunt J; Messiou C; Parker C; Dearnaley D; Swennenhuis JF; Terstappen LW; Lee G; Kheoh T; Molina A; Ryan CJ; Small E; Scher HI; de Bono JS
J Clin Oncol; 2010 Mar; 28(9):1489-95. PubMed ID: 20159823
[TBL] [Abstract][Full Text] [Related]
18. Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium.
Bradley DA; Daignault S; Ryan CJ; Dipaola RS; Cooney KA; Smith DC; Small E; Mathew P; Gross ME; Stein MN; Chen A; Pienta KJ; Escara-Wilke J; Doyle G; Al-Hawary M; Keller ET; Hussain M
Invest New Drugs; 2011 Dec; 29(6):1432-40. PubMed ID: 20336348
[TBL] [Abstract][Full Text] [Related]
19. The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy.
Sonpavde G; Pond GR; Berry WR; de Wit R; Eisenberger MA; Tannock IF; Armstrong AJ
Cancer; 2011 Sep; 117(17):3963-71. PubMed ID: 21365623
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer.
McHugh D; Eisenberger M; Heath EI; Bruce J; Danila DC; Rathkopf DE; Feldman J; Slovin SF; Anand B; Chu R; Lackey J; Reyno L; Antonarakis ES; Morris MJ
Invest New Drugs; 2019 Oct; 37(5):1052-1060. PubMed ID: 30725389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]